AfricaPress-Kenya: Britain’s AstraZeneca has agreed to buy US drugmaker Alexion Pharmaceuticals for Sh40 billion ($39 billion) in its largest ever deal, diversifying from its cancer business in a bet on rare-disease and immunology drugs.
The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its Covid-19 vaccine could be 90 per cent effective as a rival shot from Pfizer was launched in Britain and approved for use in the US.
